Surface Oncology, Inc. (SURF) News

Surface Oncology, Inc. (SURF)

Today's Latest Price: $7.75 USD

0.11 (-1.40%)

Updated Nov 24 4:00pm

Add SURF to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter SURF News Items

SURF News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest SURF News From Around the Web

Below are the latest news stories about Surface Oncology Inc that investors may wish to consider to help them evaluate SURF as an investment opportunity.

Surface Oncology +5.8% as Wedbush sees 126% upside

Surface Oncology (SURF) wrapped up after-hours trading up 5.8% after drawing a new Outperform rating from Wedbush. The firm set its price target matching a Street high $12, implying 126% upside. Wall Street analysts are Very Bullish on Surface; it has a Quant Rating of Neutral....

Seeking Alpha | August 28, 2020

3 “Strong Buy” Penny Stocks With Massive Upside Ahead

Penny stocks, you either love them or you hate them. One of the obvious draws of these stocks trading for under $5 per share is the ability to get more bang for your buck. And should these bargain priced stocks see their share prices rise by only a small amount, the rewards can be staggering.However, before jumping right into an investment in a penny stock, Wall Street pros advise looking at the bigger picture and considering other factors beyond just the price tag. For some names that fall into this category, you really do get what you pay for, offering little in the way of long-term growth prospects thanks to weak fundamentals, recent headwinds or even large outstanding share counts.Taking the risk into consideration, we used TipRanks’ database to see if we could find compelling penny...

Yahoo | June 12, 2020

Do Hedge Funds Love Surface Oncology, Inc. (SURF)?

In this article we will take a look at whether hedge funds think Surface Oncology, Inc. (NASDAQ:SURF) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]

Yahoo | June 11, 2020

Surface Oncology Announces Change to Location and Format of 2020 Annual Meeting of Stockholders

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that its 2020 Annual Meeting of Stockholders has been changed to a virtual meeting as a result of continuing concerns surrounding the COVID-19 pandemic. Stockholders will only be able to participate in this year’s Annual Meeting via the virtual meeting. This change is reflective of the public health impact of the COVID-19 pandemic, government restrictions limiting the size of gatherings, and supporting the health and well-being of Surface Oncology’s stockholders, directors and employees, and their communities.

Yahoo | May 28, 2020

Stock Alert: Surface Oncology Shares Up 36% In Premarket

Shares of Surface Oncology (SURF) are up over 36% in pre-market today, after the company announced that it has entered into a clinical trial collaboration with Merck (MRK), known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface's SRF617, an investigational antibody therapy targeting CD39, with Merck's KEYTRUDA (pembrolizumab), the first anti-PD-1 therapy approved in the United States.

RTT News | May 20, 2020

P/E Ratio Insights for Surface Oncology

Looking into the current session, Surface Oncology Inc. (NASDAQ: SURF) shares are trading at $3.44, after a 29% gain. Moreover, over the past month, the stock spiked by 21.99%, but in the past year, fell by 12.91%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session.The stock is currently higher from its 52 week low by 199.14%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with biotechnology stocks, and capitalize on the lower share price observed over the year.The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's cur...

Yahoo | May 20, 2020

Surface Oncology Fully Utilizes its $30M At-the-Market Facility

Surface Oncology  (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today that it has raised gross proceeds of approximately $28.9 million through its At-the-Market, or ATM, facility with participation based on interest received from EcoR1 Capital LLC, Venrock Healthcare Capital Partners, BVF Partners L.P., and RS Investments, a Victory Capital investment franchise. Surface Oncology sold approximately 10.9 million shares of its common stock at a purchase price of $2.66, the market price at the time of the sale. JonesTrading Institutional Services LLC is acting as the sales agent for the ATM facility.

Yahoo | May 20, 2020

Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients

Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck (MRK), known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF617, an investigational antibody therapy targeting CD39, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. This combination will be studied as a component of the first-in-human Phase 1/1b study of SRF617 and will be evaluated in patients with solid tumors, with a focus on patients with gastric cancer and those who have developed resistance to checkpoint inhibition — both area...

Yahoo | May 20, 2020

Upgrade: Analysts Just Made A Massive Increase To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

Surface Oncology, Inc. (NASDAQ:SURF) shareholders will have a reason to smile today, with the analysts making...

Yahoo | May 15, 2020

Surface Oncology to Present Preclinical Data for Multiple Product Programs at the American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass., May 15, 2020 -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.

Yahoo | May 15, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5886 seconds.